Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 88% Improvement Relative Risk Tanioka et al. Ivermectin for COVID-19 Prophylaxis Is prophylaxis with ivermectin beneficial for COVID-19? Ecological study in multiple countries Lower mortality with ivermectin (p=0.002) Tanioka et al., medRxiv, doi:10.1101/2021.03.26.21254377 Favors ivermectin Favors control

Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?

Tanioka et al., medRxiv, doi:10.1101/2021.03.26.21254377 (Preprint)
Tanioka et al., Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?, medRxiv, doi:10.1101/2021.03.26.21254377 (Preprint)
Mar 2021   Source   PDF  
  All Studies   Meta
Retrospective study of the 31 onchocerciasis-endemic countries using the community-directed treatment with ivermectin (CDTI) and the 22 non-endemic countries in Africa, showing significantly lower mortality per capita in the countries using ivermectin.
This is the 45th of 97 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion). 46 studies are RCTs, which show efficacy with p=0.00000014. This study is excluded in the after exclusion results of meta analysis: not a typical trial, analysis of African countries that used or did not use ivermectin prophylaxis for parasitic infections.
risk of death, 88.2% lower, RR 0.12, p = 0.002, relative mean mortality per million.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Tanioka et al., 26 Mar 2021, retrospective, ecological study, multiple countries, preprint, 3 authors, dosage 200μg/kg, dose varied, typically 150-200μg/kg.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Why COVID-19 is not so spread in Africa: How does Ivermectin affect it?
Hisaya Tanioka, Sayaka Tanioka, Kimitaka Kaga
Background: Scientists have so far been unable to determine the reason for the low number of COVID-19 cases in Africa. Objective: To evaluate the impact of ivermectin interventions for onchocerciasis on the morbidity, mortality, recovery, and fatality rates caused by COVID-19. Method: A retrospective statistical analysis study of the impact of ivermectin against COVID-19 between the 31 onchocerciasis-endemic countries using the community-directed treatment with ivermectin (CDTI) and the non-endemic 22 countries in Africa. The morbidity, mortality, recovery rate, and fatality rate caused by COVID-19 were calculated from the WHO situation report in Africa. We investigated the onchocerciasis endemic 31 countries and the non-endemic 22 countries. Statistical comparisons used by the Welch test of them in the two groups were made. Results: The morbidity and mortality were statistically significantly less in the 31 countries using CDTI. The recovery and fatality rates were not statistically significant difference. The average life expectancy was statistically significantly higher in the non-endemic countries. Conclusions: The morbidity and mortality in the onchocerciasis endemic countries are lesser than those in the non-endemic ones. The community-directed onchocerciasis treatment with ivermectin is the most reasonable explanation for the decrease in morbidity and fatality rate in Africa. In areas where ivermectin is distributed to and used by the entire population, it leads to a significant reduction in mortality.
H.T. and S.T. analyzed the data and wrote the first draft. All authors provided critical revisions. All authors contributed equally to this study and approved the submitted manuscript.
Ahmed, Karim, Ross, A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, doi:10.1016/j.ijid.2020.11.191
Canga, Prieto, Liébana, The Pharmacokinetics and Interactions of Ivermectin in Humans-A Mini-review, AAPS, doi:10.1208/s12248-007-9000-9
Iqbal, Abid, Hussain, The effects of regional climatic condition on the spread of COVID-19 at global scale, Sci Total Environ, doi:10.1016/j.scitotenv.2020.140101
Malik, Ansari, Ganesh, BCG vaccine: a hope to control COVID-19 pandemic amid crisis, Hum Vaccin Immunother, doi:10.1080/21645515.2020.1818522
Mehta, Mytton, Mullins, SARS-CoV-2 (COVID-19): What Do We Know About Children? A Systematic Review, Clin Infect Dis, doi:10.1093/cid/ciaa556
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop